<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02575807</url>
  </required_header>
  <id_info>
    <org_study_id>ADU-CL-11</org_study_id>
    <nct_id>NCT02575807</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer</brief_title>
  <acronym>SEASCAPE</acronym>
  <official_title>A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aduro Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aduro Biotech, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 2-part, Phase 1/2 study will test investigational cancer drugs known as CRS-207,
      epacadostat, and pembrolizumab. The purpose of this study is to find out how safe it is to
      give the investigational drugs to women with platinum-resistant ovarian, fallopian tube, or
      peritoneal cancer and if it helps patients with these types of cancer live longer or can help
      shrink or slow the growth of cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Number of patients reporting hematologic and non-hematologic DLTs</measure>
    <time_frame>Through study completion, approximately 12 months</time_frame>
    <description>DLT=dose-limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 and Phase 2: Adverse events by CTCAE grade</measure>
    <time_frame>Through study completion and safety follow up, approximately 24 months</time_frame>
    <description>CTCAE=common terminology criteria for adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: ORR will be measured, defined as CR or PR as determined by mRECIST</measure>
    <time_frame>approximately 24 months from initiation of Phase 2</time_frame>
    <description>ORR=overall response rate, CR=complete response, PR=partial response, mRECIST=modified response evaluation criteria in solid tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: PFS will be measured, defined as the time from the date of first dose to PD or death due to any cause</measure>
    <time_frame>approximately 24 months from initiation of Phase 2</time_frame>
    <description>PFS=progression-free survival, PD=disease progression</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Platinum-resistant Ovarian Cancer</condition>
  <condition>Platinum-resistant Fallopian Cancer</condition>
  <condition>Platinum-resistant Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1 Arm 1 CRS-207/Epacadostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRS-207: 1×10^9 CFU by IV infusion over 1 hour Epacadostat: 100 or 300 mg Oral BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Arm 2 CRS-207</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRS-207: 1×10^9 CFU by IV infusion over 1 hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Arm 1 CRS-207/Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab: 200 mg by IV infusion over 30 minutes CRS-207: 1×10^9 CFU by IV infusion over 1 hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Arm 2 CRS-207/Pembro/Epacadostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab: 200 mg by IV infusion over 30 minutes CRS-207: 1×10^9 CFU by IV infusion over 1 hour Epacadostat: 300 mg Oral BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CRS-207</intervention_name>
    <description>via IV infusion</description>
    <arm_group_label>Phase 1 Arm 1 CRS-207/Epacadostat</arm_group_label>
    <arm_group_label>Phase 1 Arm 2 CRS-207</arm_group_label>
    <arm_group_label>Phase 2 Arm 1 CRS-207/Pembrolizumab</arm_group_label>
    <arm_group_label>Phase 2 Arm 2 CRS-207/Pembro/Epacadostat</arm_group_label>
    <other_name>Live-attenuated double-deleted (LADD) Listeria monocytogenes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epacadostat</intervention_name>
    <description>PO BID</description>
    <arm_group_label>Phase 1 Arm 1 CRS-207/Epacadostat</arm_group_label>
    <arm_group_label>Phase 2 Arm 2 CRS-207/Pembro/Epacadostat</arm_group_label>
    <other_name>INCB024360</other_name>
    <other_name>IDO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>via IV infusion</description>
    <arm_group_label>Phase 2 Arm 1 CRS-207/Pembrolizumab</arm_group_label>
    <arm_group_label>Phase 2 Arm 2 CRS-207/Pembro/Epacadostat</arm_group_label>
    <other_name>Keytruda®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically-confirmed disease

               -  Phase 1: Individuals with epithelial ovarian cancer, fallopian tube carcinoma, or
                  primary peritoneal carcinomas who are considered to have platinum-resistant
                  disease (progression within 6 months from completion of platinum-based
                  chemotherapy).

               -  Phase 2: Individuals with epithelial ovarian cancer, fallopian tube carcinoma, or
                  primary peritoneal carcinomas who are considered to have platinum-resistant
                  disease (progression within 6 months from completion of a minimum of 4 platinum
                  therapy cycles).

          2. Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors
             (RECIST) v1.1

          3. Agree to provide core biopsies at baseline and at Cycle 2 Day 15

          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          5. Available archived tumor tissue for central analysis

          6. Adequate organ and marrow function

        Exclusion Criteria

          1. Platinum-refractory disease (progression during the first platinum-based chemotherapy)

          2. Major surgical procedure within 4 weeks prior to Study Day 1

          3. Inaccessible tumors or for whom biopsy is contraindicated

          4. Clinically significant ascites

          5. Phase 2 only: Previous treatment with &gt;3 chemotherapy regimens for locally advanced or
             metastatic disease

          6. Active bowel obstruction, or hospitalization for bowel obstruction within 2 months
             prior to screening

          7. Require parenteral nutrition

          8. Hospitalization within 2 weeks prior to screening

          9. Received any anticancer medication or therapy in the 21 days prior to study Day 1

         10. Prior monoclonal antibody treatment within 4 weeks before study Day 1

         11. History of listeriosis or previous treatment with a listeria-based immunotherapy

         12. Known allergy to both penicillin and sulfa antibiotics

         13. Any immunodeficiency disease or immune-compromised state

         14. Received prior immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1, anti PDL-1)
             and any other antibody or drug specifically targeting T-cell costimulation or an IDO
             inhibitor

         15. Pregnant or breastfeeding

         16. Clinically significant heart disease

         17. Valvular heart disease that requires antibiotic prophylaxis for prevention of
             endocarditis

         18. History of any autoimmune disease which required systemic therapy in the past 2 years

         19. Diagnosed with another malignancy within the past 3 years

         20. Currently receiving therapy with a UDP-glucuronosyltransferase 1A9 inhibitor including
             diclofenac, imipramine, ketoconazole, mefenamic acid, and probenecid

         21. Receiving monoamine oxidase inhibitor (MAOIs) or a drug which has significant MAOI
             activity (meperidine, linezolid, methylene blue) within the 21 days before screening

         22. Had prior serotonin syndrome

         23. Has implanted medical devices that pose high risks for colonization and cannot be
             easily removed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Scottsdale Healthcare Hospitals DBA HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian cancer</keyword>
  <keyword>Fallopian cancer</keyword>
  <keyword>Primary peritoneal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

